 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
10 News |  |
- | LY3023703 / Eli Lilly
Clinical, Journal: Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated due to Clinical Drug-Induced Liver Injury. (Pubmed Central) - May 7, 2019
We studied imidazole ring substitutions to successfully mitigate reactive metabolite (RM) formation. These studies support the conclusion that RM formation may play a role in the observations of DILI and the consideration of 2-aminoimidazoles as structure alerts, due to the high likelihood of bioactivation to generate RMs.
- LY3023703 / Eli Lilly
Trial termination: A Study of [14C]-LY3023703 in Healthy Participants (clinicaltrials.gov) - Jan 28, 2014
P1, N=8, Terminated, Sponsor: Eli Lilly and Company
Suspended --> Terminated; Due to safety results from another trial of LY3023703. No participants in this study received study drug.
- ||| LY3023703 / Eli Lilly
Trial completion: A Multiple Dose Study of LY3023703 in Healthy Participants (clinicaltrials.gov) - Dec 15, 2013
P1, N=90, Completed, Sponsor: Eli Lilly and Company
No participants in this study received study drug. Active, not recruiting --> Completed
- |||| LY3023703 / Eli Lilly
Trial completion: A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal (clinicaltrials.gov) - Dec 10, 2013
P2, N=130, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- LY3023703 / Eli Lilly
New P1 trial: A Study of [14C]-LY3023703 in Healthy Participants (clinicaltrials.gov) - Oct 16, 2013
P1, N=8, Terminated, Sponsor: Eli Lilly and Company
- ||||| LY3023703 / Eli Lilly
New P2 trial: A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal (clinicaltrials.gov) - Jun 5, 2013
P2, N=130, Completed, Sponsor: Eli Lilly and Company
- ||| LY3023703 / Eli Lilly
New P1 trial: A Multiple Dose Study of LY3023703 in Healthy Participants (clinicaltrials.gov) - May 6, 2013
P1, N=90, Completed, Sponsor: Eli Lilly and Company
- | LY3023703 / Eli Lilly
Trial completion: A Single Dose Study of LY3023703 in Healthy Participants (clinicaltrials.gov) - Sep 27, 2012
P1, N=30, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Completed
- | LY3023703 / Eli Lilly
New P1 trial: A Single Dose Study of LY3023703 in Healthy Participants (clinicaltrials.gov) - Jul 1, 2012
P1, N=30, Completed, Sponsor: Eli Lilly and Company